Form 4: CONMED Corp Executive Matthew Schabacker Reports Stock Option Grant

Matthew Schabacker, VP GM Advanced Surgical at CONMED Corp, reports the acquisition of 31,675 stock options.

Summary

• On April 28, 2025, Matthew Schabacker, VP GM Advanced Surgical at CONMED Corp, acquired 31,675 stock options.
• The options have an exercise price of $50.84.
• These options were granted under the company's 2018 Long-Term Incentive Plan and vest in equal amounts over a five-year period.
• Following the transaction, Schabacker directly owns 31,675 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine executive compensation disclosure. The grant itself is neither overwhelmingly positive nor negative.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.

Industry Context

Stock option grants are a common form of executive compensation in the medical device industry, used to attract and retain talent and align their interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in the healthcare and medical device sectors.
• Companies like Stryker, Medtronic, and Johnson & Johnson also utilize stock options as part of their long-term incentive plans for executives.
• The vesting schedule of five years is fairly typical for such grants, aligning with long-term performance goals.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholder sentiment as it aligns executive interests with company performance.

Key Dates

Keywords

stock options, CONMED Corp, Form 4, executive compensation, Matthew Schabacker, CNMD, insider trading